Feng Yuhua Li

US Patent:

7537765, May 26, 2009

Filed:

May 24, 2004

Appl. No.:

10/851637

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

Panacos Pharmaceuticals, Inc. - Gaithersburg MD
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/21
A61K 38/00

US Classification:

4241841, 530300, 4241861, 4241871, 4241881

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

8318425, Nov 27, 2012

Filed:

Jul 6, 2009

Appl. No.:

12/498157

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Brookings SD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department & Human Services - Washington DC
Myrexis, Inc. - Salt Lake City UT

International Classification:

C12Q 1/70
C12Q 1/68
A01N 61/00
A01N 57/00
A61K 31/00
A61K 31/66

US Classification:

435 61, 435 5, 435 611, 435 612, 514 1, 514120, 514510

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20040265320, Dec 30, 2004

Filed:

Jan 29, 2004

Appl. No.:

10/766528

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl Wild - Gaithersburg MD, US
Graham Allaway - Darnestown MD, US
Eric Freed - Frederick MD, US

International Classification:

A61K039/42

US Classification:

424/160100

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20060154718, Jul 13, 2006

Filed:

Jan 12, 2005

Appl. No.:

11/034155

Inventors:

Rodney Willyard - Flower Mound TX, US
Naveen Malhotra - Murphy TX, US
Feng Li - Plano TX, US
Keith Riggs - Frisco TX, US
Yuhua Li - Plano TX, US

International Classification:

A63F 13/00

US Classification:

463025000

Abstract:

A method employs a database table that contains progressive prize pool status data for each progressive game that may be available in a given gaming system. Additional database tables store definitions for both contributions to the various progressive prize pools and awards to be made from the various progressive prize pools. A given game play request in the gaming system is identified with a particular contribution definition from the applicable database table in order to properly update the applicable progressive prize pool in view of the game play request and the wager associated with that game play request. Also, a given result in a game offered through the gaming system is identified with a particular award definition in order to identify when a progressive prize is to be awarded and to properly award the applicable progressive prize and update the progressive prize pool.

US Patent:

20080200550, Aug 21, 2008

Filed:

May 24, 2005

Appl. No.:

11/597431

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

V.I. TECHNOLOGIES, INC. - Gaithersburg MD
THE GOV. OF US AS REP. BY THE SEC. DEP. OF HEALTH - Rockville MD

International Classification:

A61K 31/557

US Classification:

514573

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20080233559, Sep 25, 2008

Filed:

Dec 21, 2007

Appl. No.:

11/962315

Inventors:

Karl SALZWEDEL - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

International Classification:

C12Q 1/70

US Classification:

435 5

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.